Champions Oncology (CSBR) Gross Profit (2017 - 2026)

Champions Oncology (CSBR) has 10 years of Gross Profit data on file, last reported at $7.7 million in Q3 2026.

• On a quarterly basis, Gross Profit rose 28.3% year-over-year to $7.7 million in Q3 2026; TTM through Jul 2026 was $30.2 million, a 9.63% increase from a year earlier, with the FY2026 full-year figure at $28.5 million, changed 0.11% from the prior year.
• Gross Profit for Q3 2026 stood at $7.7 million, up from $7.0 million in the prior quarter.
• Across five years, Gross Profit topped out at $10.4 million in Q1 2025 and bottomed at $4.2 million in Q1 2024.
• Historically, Gross Profit has averaged $6.5 million across 5 years, with a median of $6.7 million in 2022.
• The widest annual swing landed in 2023, when Gross Profit retreated 27.54%; it then soared 149.93% in 2025.
• Year by year, Gross Profit stood at $6.8 million in 2022, then retreated by 27.54% to $5.0 million in 2023, then gained by 22.32% to $6.1 million in 2024, then gained by 28.25% to $7.8 million in 2025, then declined by 0.96% to $7.7 million in 2026.
• Per Business Quant data, the three most recent Gross Profit figures were $7.7 million in Q3 2026, $7.0 million in Q2 2026, and $7.7 million in Q1 2026.